Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Navidea Biopharmaceuticals Inc (NAVB)

Navidea Biopharmaceuticals Inc (NAVB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 60,727
  • Shares Outstanding, K 27,985
  • Annual Sales, $ 660 K
  • Annual Income, $ -10,950 K
  • 60-Month Beta 1.80
  • Price/Sales 58.02
  • Price/Cash Flow N/A
  • Price/Book 3.76
Trade NAVB with:

Options Overview

Details
  • Implied Volatility 149.23%
  • Historical Volatility 72.84%
  • IV Percentile 35%
  • IV Rank 18.06%
  • IV High 417.79% on 07/09/20
  • IV Low 90.03% on 05/08/20
  • Put/Call Vol Ratio 0.75
  • Today's Volume 7
  • Volume Avg (30-Day) 250
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 1,365
  • Open Int (30-Day) 3,051

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.10
  • Number of Estimates 1
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.00 +2.50%
on 03/05/21
3.15 -34.92%
on 02/09/21
-0.76 (-27.05%)
since 02/08/21
3-Month
1.84 +11.72%
on 12/15/20
3.15 -34.92%
on 02/09/21
+0.02 (+0.99%)
since 12/08/20
52-Week
0.63 +225.40%
on 04/16/20
5.36 -61.73%
on 07/21/20
+1.00 (+95.24%)
since 03/06/20

Most Recent Stories

More News
Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announces that management...

NAVB : 2.05 (-5.53%)
Navidea Biopharmaceuticals Announces $5 Million Private Placement with Existing Investor

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce...

NAVB : 2.05 (-5.53%)
Navidea Biopharmaceuticals Announces Submission of Formal Type B Meeting Request with FDA and Launch of NAV3-32 Phase 2B Trial in Rheumatoid Arthritis

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce...

NAVB : 2.05 (-5.53%)
Navidea Biopharmaceuticals to Present at the 2021 ICR Conference On January 14, 2021

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that...

NAVB : 2.05 (-5.53%)
Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the...

NAVB : 2.05 (-5.53%)
New Strong Sell Stocks for December 8th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

BVN : 11.29 (-2.00%)
NAVB : 2.05 (-5.53%)
STAF : 0.7900 (+1.28%)
WTER : 1.1100 (+0.91%)
PROS : 12.59 (unch)
Navidea Biopharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 12,...

NAVB : 2.05 (-5.53%)
Navidea Biopharmaceuticals Reports Third Quarter and Year-to-Date 2020 Financial Results

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its...

NAVB : 2.05 (-5.53%)
Navidea Biopharmaceuticals Announces Positive Results Encompassing Additional Patients From Its Ongoing Phase 2B Study in Rheumatoid Arthritis

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce...

NAVB : 2.05 (-5.53%)
Navidea Biopharmaceuticals to Host Third Quarter 2020 Earnings Conference Call and Corporate Update

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it...

NAVB : 2.05 (-5.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents for diseases such as cancer and Alzheimer. The Company's radiopharmaceutical development programs include: Lymphoseek(R), AZD4694 and...

See More

Key Turning Points

3rd Resistance Point 2.32
2nd Resistance Point 2.25
1st Resistance Point 2.15
Last Price 2.05
1st Support Level 1.98
2nd Support Level 1.91
3rd Support Level 1.81

See More

52-Week High 5.36
Fibonacci 61.8% 3.55
Fibonacci 50% 2.99
Fibonacci 38.2% 2.44
Last Price 2.05
52-Week Low 0.63

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar